Type 1 diabetes is the result of a selective immune-mediated destruction of the insulin-producing β-cells in the islets of Langerhans in the pancreas ([@B1]). Partial remission of type 1 diabetes often is seen in children and adolescents soon after initiating insulin treatment, and it is characterized by continuous and effective endogenous insulin secretion. After this period of remission of variable duration, the autoimmune cellular-mediated destruction of the β-cells continues and the endogenous insulin production declines gradually ([@B2]--[@B4]).

The Diabetes Control and Complication Trial (DCCT) showed that a significant proportion of adults had sustained β-cell function several years after the onset of type 1 diabetes ([@B5]), and some type 1 diabetic patients even have detectable C-peptide after 50 years of diabetes ([@B6]). In adults, residual β-cell function (RBF) may have positive effects on diabetes regulation and complications. RBF may reduce the risk of hypoglycemia, improve metabolic control estimated by HbA~1c~, lower exogenous insulin requirements, and lower the risk of long-term complications ([@B5],[@B7]--[@B13]). Based on data from the DCCT adult population, it was reported that the incidence of severe hypoglycemia varied with differences in RBF ([@B7]). In the group with the highest RBF, the lowest incidence of hypoglycemia occurred ([@B7]). Yet, even those with "minimal" RBF, defined as stimulated C-peptide level of 0.04--0.2 nmol/L, showed lower incidence of severe hypoglycemia compared with the group with undetectable RBF ([@B7]).

In children, the majority of studies of RBF have focused on the first year after clinical diagnosis ([@B14]--[@B18]). Data for RBF in children during later stages of type 1 diabetes and its effect on metabolic control and complications are scarce. In a population of 151 children with type 1 diabetes for 3 years, 23% had a stimulated C-peptide level of \>0.06 nmol/L ([@B19]). Furthermore, in a case-control study, it was demonstrated that RBF was significantly higher in children without severe hypoglycemia compared with children with severe hypoglycemia ([@B20]).

The increasing incidence of diabetes in children with reduced contribution of high-risk HLA haplotypes ([@B21],[@B22]) may have changed the type 1 diabetes phenotype toward an increased number of children with detectable C-peptide years after diagnosis, which may have favorable effects on the incidence of severe hypoglycemia and glycemic control. Therefore, the aims of this study were to investigate the phenotypical characteristics regarding RBF among Danish children with type 1 diabetes for a duration of 3--6 years; to examine possible benefits of RBF on the incidence of severe hypoglycemia, glycemic control, and insulin requirements; and, finally, to evaluate the data to determine whether there is a lower limit of RBF at which RBF exerts beneficial effect on the incidence of severe hypoglycemia and metabolic control.

RESEARCH DESIGN AND METHODS {#s1}
===========================

Patients {#s2}
--------

Participants were identified from the registry of the Danish Study Group for Childhood Diabetes (DanDiabKids) and the associated biobank. The registry comprises all Danish children and adolescents with onset of type 1 diabetes before the age of 15 years. Information on children with diagnoses of type 1 diabetes for \>3 years but \<6 years was retrieved from the registry. Of 564 eligible children, 348 children and adolescents from 16 pediatric diabetes centers within Denmark agreed to participate in the study. Six children did not complete both blood samplings of the C-peptide stimulation test, leaving 342 children and adolescents with complete data for inclusion in the study.

Information regarding incidents of severe hypoglycemia within the past 12 months before participation was retrieved by interviewing patients and their guardians, as well as by reviewing their medical records. Similarly, current insulin administration form, dose, and the last HbA~1c~ level were retrieved. From the registry, information regarding the annual centrally measured HbA~1c~ level was obtained for patients (participants) as well as for the 222 eligible patients who declined participation or who did not complete the stimulation test (nonparticipants). To compare age and diabetes duration in participants versus nonparticipants, we used the age and duration of type 1 diabetes at the date of initiation of the project.

Mixed-meal stimulation test {#s3}
---------------------------

The patients met at their usual outpatient clinic after an overnight fast, before using their morning insulin. If patients were treated with insulin by pen, then all morning insulin components were suspended before the mixed-meal stimulation test. Of 210 patients treated with multiple daily subcutaneous insulin injections, 124 were treated with basal insulin twice daily, whereas basal insulin was administered once daily during the evening to 59 patients (glargine for 5 patients) and once daily during the morning to 27 patients (glargine for 25 patients). If treated with continuous subcutaneous insulin, then the basal insulin was continued at a 25% reduced rate during fasting and during the mixed-meal test period. All patients underwent primary fasting blood sampling, followed by ingestion of a standardized liquid breakfast meal (6 mL/kg body weight; maximum, 360 mL; Boost drink/Sustacal, 237 mL containing 33 g carbohydrates, 15 g protein, 6 g fat, and 240 kcal). After 90 min, a blood sample was collected for analysis of meal-stimulated C-peptide concentration. All patients, except for one patient with high RBF, had meal-stimulated blood glucose \>11.2 mmol/L. Subsequently, an appropriate insulin dose was administered.

C-peptide {#s4}
---------

Standard meal--stimulated C-peptide was used to assess the RBF as previously described ([@B23]--[@B27]). Serum samples during fasting and after stimulation were collected and stored at −80°C until analysis of C-peptide concentration using a fast-phase, fluoroimmunometric sandwich assay on a 1235 AutoDELPHIA (Perkin Elmer-Wallach, Turku, Finland). The detection limit was 0.01 nmol/L and the measuring range was 0.01--6.0 nmol/L. The intra-assay coefficients of variation were 4.3% (at 0.1 nmol/L), 4.7% (at 1.0 nmol/L), and 3.6% (at 2.5 nmol/L). The interassay coefficients of variation were 5.0% (at 0.1 nmol/L), 4.5% (at 1.0 nmol/L), and 2.7% (at 2.5 nmol/L). The C-peptide unit conversion (approximation) was performed as follows: C-peptide (ng/mL) = (3.0 × C-peptide \[nmol/L\]).

Meal-stimulated C-peptide concentrations were used for trichotomization by dividing participants into three RBF groups according to the stimulated C-peptide concentration levels reported by the DCCT study ([@B7]). Groups were defined as follows: *high-RBF* (with meal-stimulated C-peptide \>0.2 nmol/L); *low-RBF* (with C-peptide between 0.04 and 0.2 nmol/L); and *non-RBF* (with C-peptide \<0.04 nmol/L including undetectable C-peptide). The C-peptide concentration of 0.04 nmol/L was chosen as the cutoff for RBF when considering RBF as a dichotomous outcome (with or without RBF) because it was shown in the DCCT ([@B7]) to be the lower concentration limit of clinical relevance in adults.

Incidence of severe hypoglycemia {#s5}
--------------------------------

An incident of severe hypoglycemia was defined as an incident of confirmed hypoglycemia that led to loss of consciousness or seizure or both. The incidence is reported as incidence proportion, and it is given as the proportion of participants experiencing an incident within the past year per 100 participants.

HbA~1c~ {#s6}
-------

HbA~1c~ levels were measured at the participants' local outpatient clinic (current HbA~1c~) as well as once during an annual centrally measured sample as part of the DanDiabKids registry and biobank (annual HbA~1c~). HbA~1c~ was measured by high-performance liquid ion exchange or affinity chromatography standardized according to the American National Glycohemoglobin Standardization Program (NGSP), and is referred to as the NGSP standard (%) and as the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) standard (mmol/mol) ([@B28]). HbA~1c~ unit conversion (approximation) was performed as follows: HbA~1c~ (IFCC) = 10.93 × HbA~1c~ (NGSP) % − 23.5.

HLA genotyping {#s7}
--------------

HLA typing (DQB1) was performed as previously described ([@B29]). The HLA-DQB1 types were classified as follows: very high-risk genotypes (302/02); high-risk genotypes (302/302 and 302/X, where X is any allele except 02); moderate-risk genotypes (02/02 and 02/X, where X is any allele except 0302); and low-risk genotypes (604/x, 604/301, 603/304, 602/304, 602/301, 603/x, 602/x, 304/x, and 301/x).

Ethics {#s8}
------

The Danish National Committee on Biomedical Research Ethics and the Danish Study Group for Childhood Diabetes approved the study. All participants and their parents or guardians provided written informed consent.

Statistical analysis {#s9}
--------------------

Student *t* tests (two-tailed), Wilcoxon rank-sum tests, or χ^2^ tests were used when appropriate. Spearman correlations were used for evaluation of the association between non-normally distributed data. Logistic regression was used when evaluating severe hypoglycemia as a dichotomous outcome, and when evaluating HbA~1c~ levels \<7.5% versus ≥7.5% as a dichotomous outcome. Multiple linear regression was used to evaluate the following: the association between current HbA~1c~ \[transformed by natural logarithm (*logHbA*~1c~)\] as the dependent variable and RBF, with RBF divided into groups as the independent variable, and the association between insulin requirement {transformed by natural logarithm \[*log*(*insulin requirement*)\]} as the dependent variable and the RBF groups as the independent variable. The estimated differences in the ln scale were consequently exponentiated to obtain ratios of the medians, which are presented later. A variable with a possible independent effect on HbA~1c~ levels is the center effect. This possible effect was investigated by the application of standardized *z* scores for HbA~1c~ as ratios between each patient's HbA~1c~ value and the mean HbA~1c~ level for that treatment center, thereby adjusting for the possible effects of differences in the absolute values of HbA~1c~ between the different treatment centers.

Estimates are provided as mean ± SE for normally distributed data or as median (interquartile range) for skewed continuous data. *P* \< 0.05 was considered statistically significant. Stata for Mac (Stata Statistical Software release 11; StataCorp, College Station, TX) statistical package was used for all analyses.

RESULTS {#s10}
=======

The study cohort of 342 children comprised 169 girls and 173 boys. The group included 61% of the total eligible population of Danish children and adolescents with type 1 diabetes for 3--6 years at the time of the study. Median age at type 1 diabetes onset was 9.2 years (interquartile range, 6.2--11.5); median age at inclusion in the study was 13.6 years (interquartile range, 10.8--15.7). Median diabetes duration was 4.2 years (interquartile range, 3.7--5.0). Four children were non-Caucasian and one child had a Danish father and a Philippine mother. Twenty-seven percent of the patients were treated by two insulin injections per day, 61% were treated by multiple subcutaneous insulin injections, and 12% were treated by continuous subcutaneous insulin injections. Patient characteristics stratified for C-peptide \<0.04 nmol/L or \>0.04 nmol/L are shown in [Table 1](#T1){ref-type="table"}.

###### 

Characteristics of the 342 patients by RBF as assessed by stimulated C-peptide

![](3454tbl1)

RBF after 3--6 years of type 1 diabetes {#s11}
---------------------------------------

A total of 160 patients (46.8%) had detectable levels of meal-stimulated C-peptide (≥0.01 nmol/L); of these, 134 (39.2%) also had detectable levels of C-peptide during the fasting state, leaving 26 patients with only detectable meal-stimulated C-peptide. A strong correlation between fasting and meal-stimulated C-peptide levels was demonstrated (Spearman ρ = 0.93; *P* \< 0.01). Ninety-two patients (27%) had meal-stimulated C-peptide concentrations (RBF) of \>0.04 nmol/L. Of these, 65 patients (19%) had RBF between 0.04 and 0.2 nmol/L (*low-RBF*) and 27 patients (8%) had RBF \>0.2 nmol/L (*high-RBF*). Eighty patients (23.3%) had stimulated RBF \>0.06 nmol/L. There was no sex difference in RBF. Older age at diabetes onset increased the probability of having stimulated RBF \>0.04 nmol/L, but 11% of children with diabetes onset before 7 years of age had stimulated RBF \>0.04 nmol/L at 3--6 years after diabetes onset ([Table 1](#T1){ref-type="table"}). Long diabetes duration increased the probability of having RBF \<0.04 nmol/L ([Table 1](#T1){ref-type="table"}).

Incidence of severe hypoglycemia {#s12}
--------------------------------

We observed the same high frequencies of severe hypoglycemia in the group with no detectable C-peptide as in the group with C-peptide \<0.04 nmol/L ([Table 2](#T2){ref-type="table"}). In the group with C-peptide \>0.04 but \<0.2 nmol/L (*low-RBF*), and in the group with C-peptide \>0.2 nmol/L (*high-RBF*), the frequency of severe hypoglycemia was considerably lower ([Table 2](#T2){ref-type="table"}). The incidence of severe hypoglycemic episodes in the *low-RBF* and *high-RBF* groups was 7.6 ± 2.8 per 100 patients, whereas in the *non-RBF* group it was 17.6 ± 2.4 per 100 participants ([Table 1](#T1){ref-type="table"}). Hence, the odds ratio (OR) for having a hypoglycemic incident in the *non-RBF* group compared with the *low-RBF* and *high-RBF* groups was 2.59 (95% CI, 1.10--7.08; *P* \< 0.03). When adjusting for age, diabetes duration, sex, HbA~1c~ level, daily insulin requirement, and insulin administration technique, logistic regression analysis revealed an adjusted OR of 2.65 (95% CI, 1.10--6.35; *P* \< 0.03). Mean HbA~1c~ in the group with hypoglycemia did not differ from that in the group without hypoglycemia (8.47 ± 0.17% \[69.1 ± 1.9 mmol/mol\] vs. 8.31 ± 0.08% \[67.3 ± 0.9 mmol/mol\]; *P* = 0.44). Mean daily insulin dose for the group with hypoglycemia was not different from that for the group without hypoglycemia (1.08 ± 0.04 units/kg/day vs. 1.06 ± 0.02 units/kg/day; *P* = 0.74).

###### 

Frequency of hypoglycemia by stimulated RBF
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Metabolic control {#s13}
-----------------

Mean HbA~1c~ (±SE) in the total population was 8.33 ± 0.07% (67.5 ± 0.8 mmol/mol). When comparing the groups according to RBF, higher RBF levels were associated with lower current HbA~1c~. Mean HbA~1c~ levels were 8.49 ± 0.08% (69.3 ± 0.09 mmol/mol) for the *non-RBF* group, 8.10 ± 0.16% (65.0 ± 1.7 mmol/mol) for the *low-RBF* group, and 7.47 ± 0.18% (58.1 ± 2.0 mmol/mol) for the *high-RBF* group ([Table 3](#T3){ref-type="table"}). The HbA~1c~ levels thereby were reduced in the *low-RBF* group by 4.5% (*P* \< 0.05) and by 12.0% (*P* \< 0.01) (unadjusted levels) for the *high-RBF* group as compared with the *non-RBF* group. The difference between the *low-RBF* and *high-RBF* groups also was significant (*P* \< 0.03) ([Table 3](#T3){ref-type="table"}). Multiple regression analysis using the current HbA~1c~ levels (log HbA~1c~) as the dependent variable adjusting for sex, age, pubertal status, diabetes duration, and insulin administration technique showed adjusted HbA~1c~ level reductions of 5.3% (*P* \< 0.01) for the *low-RBF* group and 12.9% (*P* \< 0.01) for the *high-RBF* group as compared with the *non-RBF* group ([Table 3](#T3){ref-type="table"}). The adjusted difference between the *low-RBF* and *high-RBF* groups also was significant (*P* \< 0.03). The likelihood of having HbA~1c~ \<7.5% was found to be significantly associated with RBF levels and was found to be different across all three groups ([Table 3](#T3){ref-type="table"}), with proportions of participants having below-target levels being 18.4, 32.3, and 51.9% in the *non-RBF*, *low-RBF*, and *high-RBF* groups, respectively. Logistic regression revealed adjusted ORs for having HbA~1c~ \<7.5% to be 2.03 (*P* \< 0.02) in the *low-RBF* group and 5.29 (*P* \< 0.001) in the *high-RBF* group as compared with the *non-RBF* group.

###### 

Basic characteristics, HbA~1c~, and insulin requirements by RBF groups
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Metabolic control and center effect {#s14}
-----------------------------------

Multiple regression analysis using the standardized HbA~1c~ level as the dependent variable yielded adjusted HbA~1c~ reductions of 4.6% (95% CI, 0.6--8.7; *P* \< 0.03) for the *low-RBF* group and 10.7% (95% CI, 4.8--16.6; *P* \< 0.001) for the *high-RBF* group as compared with the *non-RBF* group. The HbA~1c~ reductions in the *low-RBF* and *high-RBF* groups were approximately the same as those obtained when multiple regression analysis was conducted with the current HbA~1c~ as the dependent variable instead of the standardized HbA~1c~. Therefore, the center effect seems negligible.

Insulin requirement {#s15}
-------------------

The insulin requirements showed significant differences between the *high-RBF* and the *low-RBF* and *non-RBF* groups (*P* \< 0.05 and *P* \< 0.05, respectively). No significant difference was detected between the *low-RBF* and *non-RBF* groups ([Table 3](#T3){ref-type="table"}). Multiple regression analysis revealed that the crude association did not change when adjusting for sex, age, pubertal status, diabetes duration, and insulin administration technique.

Participants compared with nonparticipants {#s16}
------------------------------------------

Comparisons between participants and nonparticipants did not show any significant differences in sex, age at type 1 diabetes onset, diabetes duration, or mean annual HbA~1c~. Complete information for 20% of the participants and nonparticipants was not available from the registry.

CONCLUSIONS {#s17}
===========

The current study characterizes RBF evaluated as stimulated C-peptide 3--6 years after diabetes onset in a homogeneous, Danish, type 1 diabetic population. The study group included 342 children and adolescents, of whom 97% were positive for one or more diabetes-specific autoantibodies at diabetes onset ([@B29]). Great diversity concerning RBF phenotype was observed. We demonstrated that the group with RBF \>0.04 nmol/L had significantly lower frequency of severe hypoglycemia and significantly lower HbA~1c~.

In total, 47% of the children had a meal-stimulated C-peptide level higher than our lower detection limit of 0.01 nmol/L. Stimulated C-peptide level equal to or just higher than our lower detection limit may not affect the clinical outcome but may serve as an autoantigen stimulus ([@B29]). Schiffrin et al. ([@B19]) found that 23% of 151 Canadian children and adolescents with type 1 diabetes onset during 1985--1988 had stimulated C-peptide \>0.06 nmol/L at 3 years after diabetes onset. Remarkably, 20 years later, in our population of type 1 diabetic children the percentage with RBF \>0.06 nmol/L also was 23%. This suggests that the proportion of diabetic children with RBF after 3 years of type 1 diabetes has not changed during the past two decades. Nordwall and Ludvigsson ([@B30]) came to the same conclusion using a Swedish type 1 diabetic population of 316 children with diabetes onset during the period 1976--2000. In a population of 2,789 children and adolescents with type 1 diabetes onset after 2000 in the United States, 10.7% had fasting C-peptide \>0.08 nmol/L at 5 years after diabetes onset. However, due to the diverse ethnicity in that study population, the fact that 10% of the patients had diabetes onset in the age interval 15--19 years, and the fact that stimulated C-peptide was not performed, the study is not quite comparable to our study ([@B31]).

In patients who underwent islet transplantation, fasting C-peptide concentration \>0.1 nmol/L (0.3 ng/mL), corresponding to stimulated C-peptide of ∼0.25 nmol/L ([@B31]), confers protection from severe hypoglycemia ([@B32]); in adults with type 1 diabetes, stimulated C-peptide concentration \>0.2 nmol/L reduces the risk of severe hypoglycemia ([@B13]). We found that even lower stimulated C-peptide levels reduce the risk of severe hypoglycemia. However, our results indicate that there may be a limit of ∼0.04 nmol/L of stimulated C-peptide that confers a beneficial effect on the risk of severe hypoglycemia. Remarkably, Steffes et al. ([@B7]) also demonstrated differences in the risk of severe hypoglycemia depending on a cutoff point of stimulated RBF of 0.04 nmol/L in adults ([@B7]). Egger et al. ([@B20]) compared children who had experienced an episode of hypoglycemic coma with children without incidents of hypoglycemic coma and found significantly higher RBF in children without severe hypoglycemia compared with the children with one or more severe hypoglycemic episodes. In that study, HbA~1c~ was significantly lower in the group experiencing one or more episodes of severe hypoglycemia than in the group without hypoglycemia ([@B20]). Although mean HbA~1c~ was 9% in the group with hypoglycemia, Egger et al. ([@B20]) proposed a less tight glycemic control to reduce the frequency of severe hypoglycemia. We did not find any difference in HbA~1c~ in the groups with and without hypoglycemia, nor did we find any difference in insulin requirements. The fewer severe hypoglycemia episodes in patients with some RBF may be partly attributable to preserved α-cells with the ability to secrete glucagon ([@B7],[@B33]).

RBF correlated inversely with HbA~1c~ levels in a dose-response--like manner throughout all groups, with a lower cutoff point of 0.04 nmol/L for the *low-RBF* group; the chance of having HbA~1c~ \<7.5% also was significantly higher in the *high-RBF* group compared with the other groups. In the DCCT, the cutoff point for an effect of RBF on HbA~1c~ in adults was a stimulated C-peptide level \>0.2 nmol/L ([@B5]); however, Nordwall and Ludvigsson ([@B30]) demonstrated lower HbA~1c~ in children with fasting C-peptide \>0.1 nmol/L. Schiffrin et al. ([@B19]) did not find any association between RBF and HbA~1c~.

Daily insulin requirement was lowest in the *high-RBF* group but was not different between the *low-RBF* and the *non-RBF* groups. Patients in the *non-RBF* group may have higher glucose variability ([@B34]), making it difficult to increase the insulin dose.

Strengths of the study {#s18}
----------------------

All participants had fasting and stimulated C-peptide levels measured 90 min after ingestion of a standard meal, which is a highly sensitive and specific measure of endogenous insulin secretion ([@B27]). Two of the authors performed all the tests and blood sample procedures. All C-peptide analyses were completed in two batches. The study group was a homogeneous Danish population with only a few non-Caucasians.

Limitations of the study {#s19}
------------------------

Thirty-nine percent of children eligible for the study according to the DanDiabKids registry did not participate. However, analysis of the nonparticipant group with data available from the registry showed no difference among participants and nonparticipants regarding age at diabetes onset, diabetes duration, and the value of the last centrally registered HbA~1c~. The HbA~1c~ used for the study was analyzed locally, but we found no significant independent center effect.

Conclusion {#s20}
----------

In summary, we found in this homogenous, Danish, type 1 diabetic population of children and adolescents a considerable phenotypic diversity with respect to RBF at 3--6 years after the onset of diabetes. However, the phenotype diversity concerning RBF seems unchanged during the past 20 years. We demonstrated that RBF ≥0.04 nmol/L had a major beneficial effect on the frequency of severe hypoglycemia. Finally, we demonstrated that RBF as low as 0.04 nmol/L had a beneficial effect on HbA~1c~, whereas RBF of 0.2 nmol/L was needed to reduce the daily insulin requirements. Future efforts should focus on strategies to preserve RBF for as long as possible in children with type 1 diabetes. However, it appears that stimulated RBF of 0.04 nmol/L is the lower limit for providing beneficial effects on the frequency of severe hypoglycemia and metabolic control.
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